Ladenburg Thalmann Maintains Buy on Reata Pharmaceuticals, Raises Price Target to $122
Portfolio Pulse from richadhand@benzinga.com
Ladenburg Thalmann analyst Matthew Kaplan maintains a 'Buy' rating on Reata Pharmaceuticals (NASDAQ:RETA) and raises the price target from $104 to $122.
June 29, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals' price target has been raised from $104 to $122 by Ladenburg Thalmann, maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by Ladenburg Thalmann indicates a positive outlook for Reata Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100